Kaulfuß, Silke

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Urology Supplements"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Possner, Maria"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Strauss, A."],["dc.contributor.author","Schulz, W."],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T11:17:35Z"],["dc.date.available","2018-11-07T11:17:35Z"],["dc.date.issued","2008"],["dc.format.extent","173"],["dc.identifier.doi","10.1016/S1569-9056(08)60407-8"],["dc.identifier.isi","000253839800404"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54838"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.issn","1569-9056"],["dc.title","Functional analysis of NKX3.1 by RNA interference in LNCaP prostate cancer cells"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2626"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Molecular Cancer Therapeutics"],["dc.bibliographiccitation.lastpage","2633"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Stettner, Mark"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Burfeind, Peter"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T10:58:18Z"],["dc.date.available","2018-11-07T10:58:18Z"],["dc.date.issued","2007"],["dc.description.abstract","In the prostate, estrogen receptor beta (ER beta), the preferred receptor for phytoestrogens, has features of a tumor suppressor. To investigate the mechanisms underlying the beneficial effects on prostate cancer of histone deacetylase inhibitor valproic acid (VPA) and phytoestrogen tectorigenin, we analyzed the expression of ER after tectorigenin or VPA treatment. For further functional analysis, we knocked down ER beta expression by RNA interference. LNCaP prostate cancer cells were treated with 5 mmol/L VPA or 100 mu mol/L tectorigenin and transfected with small interfering RNA (siRNA) against ER beta. Control transfections were done with luciferase (LUC) siRNA. Expression of ER beta was assessed by Western blot. mRNA expression was quantitated by real-time reverse transcription-PCR. Expression of ER beta mRNA and protein markedly increased after VPA or tectorigenin treatment. When ER beta was knocked down by siRNA, the expression of prostate-derived Ets factor, prostate-specific antigen, prostate cancer-specific indicator gene DD3(PCA3), insulin-like growth factor-1 receptor, the catalytic subunit of the telomerase, and ER beta was up-regulated and the tectorigenin effects were abrogated. ER beta levels were diminished in prostate cancer and loss of ER beta was associated with proliferation. Here, we show that siRNA-mediated knockdown of ER beta increases the expression of genes highly relevant to tumor cell proliferation. In addition, we show that one prominent result of treatment with VPA or tectorigenin is the up-regulation of ER beta resulting in antiproliferative effects. Thus, these drugs, by restoring the regulatory function of ER in tumor cells, could become useful in the intervention of prostate cancer."],["dc.identifier.doi","10.1158/1535-7163.MCT-07-0197"],["dc.identifier.isi","000250252100003"],["dc.identifier.pmid","17913855"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50445"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1535-7163"],["dc.title","The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Oberthuer, R."],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Meyer, J."],["dc.contributor.author","Seemann, Henning"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Scharf, Jens-Gerd"],["dc.contributor.author","Burfeind, Peter"],["dc.date.accessioned","2018-11-07T09:44:05Z"],["dc.date.available","2018-11-07T09:44:05Z"],["dc.date.issued","2014"],["dc.format.extent","44"],["dc.identifier.isi","000332306700145"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34320"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Molecular mechanisms of receptor tyrosine kinase inhibition in colorectal cancer cells and indications for therapeutical options"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","393"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of the European Academy of Dermatology and Venereology"],["dc.bibliographiccitation.lastpage","394"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Boeckle, B. C."],["dc.contributor.author","Shoukier, Moneef"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Sepp, N. T."],["dc.date.accessioned","2018-11-07T09:27:49Z"],["dc.date.available","2018-11-07T09:27:49Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1111/j.1468-3083.2012.04490.x"],["dc.identifier.isi","000315115900041"],["dc.identifier.pmid","22394114"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30626"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0926-9959"],["dc.title","Mucocutaneous telangiectasia - it's the tip of the iceberg"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","451"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","457"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Salendo, Junius"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Kramer, Frank"],["dc.contributor.author","Zhang, X."],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Kaulfuß, Silke"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Dobbelstein, Matthias"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:20:18Z"],["dc.date.available","2018-11-07T09:20:18Z"],["dc.date.issued","2013"],["dc.description.abstract","Background and purpose: Preoperative chemoradiotherapy (CRT) represents the standard treatment for locally advanced rectal cancer. Tumor response and progression vary considerably. MicroRNAs represent master regulators of gene expression, and may therefore contribute to this diversity. Material and methods: Genome-wide microRNA (miRNA) profiling was performed for 12 colorectal cancer (CRC) cell lines and an individual in vitro signature of chemoradiosensitivity was established. Functional relevance of selected miRNAs was established by transfecting miRNA-mimics into SW480 and SW837 cells. The prognostic value of selected miRNAs was assessed in 128 pretherapeutic patient biopsies. Results: Thirty-six miRNAs were identified to significantly correlate with sensitivity to CRT (Q < 0.05) including miR-320a and other miRNAs involved in the MAPK-, TGF- and Wnt-pathway. Transfection of selected miRNAs (let-7g, miR-132, miR-224, miR-320a) each induced a shift of sensitivity. High expression of let-7g was associated with a good prognosis in rectal cancer patients (P = 0.03). Conclusions: This is the first report of a miRNA expression signature for in vitro chemoradiosensitivity of cell lines. Many of the identified miRNAs have not been linked to the response to CRT and may represent potential molecular targets to sensitize resistant cancers. If further validated, let7g expression may serve as predictive biomarker. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 451-457"],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179]"],["dc.identifier.doi","10.1016/j.radonc.2013.06.032"],["dc.identifier.isi","000327004700015"],["dc.identifier.pmid","23932154"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28850"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.publisher.place","Clare"],["dc.relation.conference","13th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology"],["dc.relation.eventlocation","Ermatingen, SWITZERLAND"],["dc.relation.issn","0167-8140"],["dc.title","Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a,-224,-132 and let7g"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","93"],["dc.bibliographiccitation.journal","Cancer Letters"],["dc.bibliographiccitation.lastpage","105"],["dc.bibliographiccitation.volume","407"],["dc.contributor.author","Oberthür, Rabea"],["dc.contributor.author","Seemann, Henning"],["dc.contributor.author","Gehrig, Julia"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Halpape, Rovena"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Scharf, Jens-Gerd"],["dc.contributor.author","Burfeind, Peter"],["dc.contributor.author","Kaulfuß, Silke"],["dc.date.accessioned","2020-12-10T14:22:49Z"],["dc.date.available","2020-12-10T14:22:49Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1016/j.canlet.2017.08.009"],["dc.identifier.issn","0304-3835"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71746"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1115"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Carcinogenesis"],["dc.bibliographiccitation.lastpage","1124"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Witt, Daria"],["dc.contributor.author","Burfeind, Peter"],["dc.contributor.author","von Hardenberg, Sandra"],["dc.contributor.author","Opitz, Lennart"],["dc.contributor.author","Salinas-Riester, Gabriela"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Neesen, Juergen"],["dc.contributor.author","Kaulfuss, Silke"],["dc.date.accessioned","2018-11-07T09:25:10Z"],["dc.date.available","2018-11-07T09:25:10Z"],["dc.date.issued","2013"],["dc.description.abstract","In this study, primary murine prostate cancer (PCa) cells were derived using the well-established TRAMP model. These PCa cells were treated with the histone deacetylase inhibitor, valproic acid (VPA), and we demonstrated that VPA treatment has an antimigrative, antiinvasive and antiproliferative effect on PCa cells. Using microarray analyses, we discovered several candidate genes that could contribute to the cellular effects we observed. In this study, we could demonstrate that VPA treatment of PCa cells causes the re-expression of cyclin D2, a known regulator that is frequently lost in PCa as we could show using immunohistochemical analyses on PCa specimens. We demonstrate that VPA specifically induces the re-expression of cyclin D2, one of the highly conserved D-type cyclin family members, in several cancer cell lines with weak or no cyclin D2 expression. Interestingly, VPA treatment had no effect in fibroblasts, which typically have high basal levels of cyclin D2 expression. The re-expression of cyclin D2 observed in PCa cells is activated by increased histone acetylation in the promoter region of the Ccnd2 gene and represents one underlying molecular mechanism of VPA treatment that inhibits the proliferation of cancer cells. Altogether, our results confirm that VPA is an anticancer therapeutic drug for the treatment of tumors with epigenetically repressed cyclin D2 expression."],["dc.identifier.doi","10.1093/carcin/bgt019"],["dc.identifier.isi","000318646000021"],["dc.identifier.pmid","23349020"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30001"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0143-3334"],["dc.title","Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","199"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BJU International"],["dc.bibliographiccitation.lastpage","203"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Peter, Thomas"],["dc.contributor.author","Huenermund, Anika"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Seidlova-Wuttke, Dana"],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Seseke, Florian"],["dc.date.accessioned","2018-11-07T11:00:51Z"],["dc.date.available","2018-11-07T11:00:51Z"],["dc.date.issued","2007"],["dc.description.abstract","To investigate the changes in expression underlying the marked reduction of tumour growth in vivo, by analysing the effect of Belamcanda chinensis extract (BCE) on LNCaP cells in vitro, as phytoestrogens are chemopreventive in prostate cancer, and in previous studies we examined the effects of the isoflavone tectorigenin isolated from B. chinensis on LNCaP prostate cancer cells, and a BCE consisting of 13 phytoestrogenic compounds on tumour-bearing nude mice. LNCaP cells were treated with 100, 400 or 1400 mu g/mL BCE; proliferation was assessed with an Alamar Blue assay. We used real-time reverse transcription-polymerase chain reaction to quantify mRNA expression of the androgen receptor (AR), the AR coactivator prostate derived Ets transcription factor (PDEF), NKX3.1, prostate specific antigen (PSA) and oestrogen receptor-beta (ER-beta) compared with the expression of the housekeeping gene porphobilinogen deaminase (PBGD). PSA secretion from LNCaP cells was measured and protein expression of the AR investigated by Western blot analysis. Concomitant with a marked decrease of tumour cell proliferation BCE down-regulated the expression of the AR, PDEF, NKX3.1 and PSA. In the same experiments, the expression of PBGD was unaltered, whereas ER-beta expression increased. Furthermore, AR protein and PSA secretion were markedly diminished after treatments with the BCE. BCE, comprising 13 different phytoestrogens, decreases the expression of the AR and its co-activator PDEF concomitant with diminished cell proliferation and PSA secretion. NKX3.1 expression was also reduced by BCE. We hypothesise that the positive effects of BCE are initiated by up-regulation of the ER-beta, a putative tumour-suppressor gene."],["dc.identifier.doi","10.1111/j.1464-410X.2007.06924.x"],["dc.identifier.isi","000247112400043"],["dc.identifier.pmid","17488304"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51023"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","1464-4096"],["dc.title","Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Seemann, Henning"],["dc.contributor.author","Kampe, Rovena"],["dc.contributor.author","Meyer, J."],["dc.contributor.author","Koenig, B."],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Scharf, Jens-Gerd"],["dc.contributor.author","Burfeind, Peter"],["dc.date.accessioned","2018-11-07T09:20:19Z"],["dc.date.available","2018-11-07T09:20:19Z"],["dc.date.issued","2013"],["dc.format.extent","S495"],["dc.identifier.isi","000326843603248"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28855"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO"],["dc.relation.eventlocation","Amsterdam, NETHERLANDS"],["dc.relation.issn","1879-0852"],["dc.relation.issn","0959-8049"],["dc.title","Blockade of PDGFR family together with SRC leads to diminished proliferation of CRC cells"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Oberthuer, R."],["dc.contributor.author","Meyer, J."],["dc.contributor.author","Seemann, Henning"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Scharf, Jens-Gerd"],["dc.contributor.author","Burfeind, Peter"],["dc.date.accessioned","2018-11-07T09:20:20Z"],["dc.date.available","2018-11-07T09:20:20Z"],["dc.date.issued","2013"],["dc.format.extent","S494"],["dc.identifier.isi","000326843603244"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28856"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO"],["dc.relation.eventlocation","Amsterdam, NETHERLANDS"],["dc.relation.issn","1879-0852"],["dc.relation.issn","0959-8049"],["dc.title","Dual blockade of IGF-IR and EGFR sensitizes colorectal cancer cells to 5-FU-based radiochemotherapy in vitro and in vivo"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]